H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Immunovant to $21 from $17 and keeps a Buy rating on the shares post the fiscal Q3 results. The analyst says the company is gearing up for multiple data readouts in 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant price target raised to $21 from $19 at Chardan
- Immunovant expects cash to fund operations into 2H25
- Immunovant decides not to pursue WAIHA indication for batoclimab
- Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
- Immunovant to initiate Phase 1 trial of IMVT-1402 in early 2023